Lates News

China Biopharmaceutical Co., Ltd. announced that the jointly developed Pembrolizumab Injection has been approved by the U.S. Food and Drug Administration (FDA) for the following indications: 1. In combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) in adult patients; 2. As a monotherapy for the treatment of metastatic non-keratinizing nasopharyngeal carcinoma in adult patients who have progressed during or after platinum-based chemotherapy and have received at least one other previous therapy.